A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma

Sponsor
Peking University Cancer Hospital & Institute
Study ID
NCT03422445
Phase
PHASE2
Status
Unknown

Conditions

  • Advanced Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib：500mg/d，qd，po，d1-28
  • Temozolomide — DRUG
    Temozolomide：300mg/d，qd，po，d1-5

Study Details

30 patients with advanced melanoma will receive apatinib plus Temozolomide as maintenance therapy.

Key Dates

Start date
Jan 8, 2018
Status verified
Jan 2018
Primary completion
Feb 28, 2019
Completion
Feb 28, 2019

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib plus Temozolomide
    this trial is designed single arm. all the subjects enrolled will receive the experimental intervention,apatinib+temozolomide.

Primary Outcome Measure

Progression Free Survival（PFS） [ Time Frame: 12 months ]

Central Contacts

Related Studies